

Happify Health and Zuellig Pharma partner to commercialize prescription Digital Therapeutics in Asia

16 March 2022 | News

Zuellig Pharma will license Ensemble, Happify Health's transdiagnostic prescription digital therapeutic for people with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) or both



Happify Health, the Intelligent Healing Company, has entered into an out-licensing and distribution deal with Zuellig Pharma for two of its digital therapeutics solutions.

Zuellig Pharma, one of the largest healthcare services groups in Asia, will license Happify Health's solutions through ZP Therapeutics, Zuellig Pharma's commercialization arm, to deliver precision digital healthcare at scale.

The two solutions designed to improve health outcomes for people with mental health conditions and sleep disorders are:

- A transdiagnostic prescription digital therapeutic, *Ensemble*, for the treatment of patients who have Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) or both. Designed as an adjunct to care, *Ensemble* requires a prescription and teaches people new skills and habits to take control of their symptoms.
- A prescription digital therapeutic used to treat chronic insomnia based on the principles of Cognitive Behavioral Therapy (CBT) that includes interventions, patient education and skill-building that leverages text messaging, videos, quizzes and Happify Health's conversational artificial intelligence (AI) chatbot, *Anna*.